The purpose of our meta-analysis was to examine the published data of placebo-controlled or head-to-head RCTs, which tested the efficacy and safety of various SGLT-2 inhibitors to specifically treat NAFLD in individuals with or without established T2DM. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.